VRPX RSI Chart
Last 7 days
-69.4%
Last 30 days
-77.5%
Last 90 days
-76.4%
Trailing 12 Months
-90.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 24, 2022 | sendrow jerrold | bought | 5,805 | 1.29 | 4,500 | - |
May 18, 2022 | floyd eric | bought | 6,107 | 1.3635 | 4,479 | - |
May 18, 2022 | mack anthony p. | bought | 101,505 | 1.34 | 75,750 | chief executive officer |
Nov 22, 2021 | sendrow jerrold | bought | 15,307 | 3.925 | 3,900 | - |
Nov 18, 2021 | mack anthony p. | bought | 100,249 | 3.99 | 25,125 | chief executive officer |
Feb 17, 2021 | jacob gary s | bought | 23,761 | 6.789 | 3,500 | - |
Feb 17, 2021 | jambulingam thani | bought | 716 | 7.16 | 100 | - |
Which funds bought or sold VRPX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -48.00 | - | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 64.00 | 64.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -2,022 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 6,174 | 6,174 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -3,744 | - | -% |
May 14, 2024 | NORTHERN TRUST CORP | sold off | -100 | -4,872 | - | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -2,117 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | sold off | -100 | -20,162 | - | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | sold off | -100 | -10,000 | - | -% |
May 10, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | sold off | -100 | -32,280 | - | -% |
Unveiling Virpax Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Virpax Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Virpax Pharmaceuticals, Inc. News
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -67.5% | 3,130 | 9,628 | 13,038 | 15,951 | 18,493 | 19,674 | 23,636 | 29,402 | 34,746 | 39,572 | 43,273 | 11,388 | 13,219 | - | - |
Current Assets | -67.5% | 3,130 | 9,628 | 13,038 | 15,951 | 18,493 | 19,674 | 23,636 | 29,402 | 34,746 | 39,572 | 43,273 | 11,388 | 13,219 | 73.00 | 47.00 |
Cash Equivalents | -79.6% | 1,866 | 9,142 | 12,153 | 14,804 | 16,987 | 18,995 | 20,563 | 26,061 | 30,797 | 36,842 | 41,713 | 10,467 | 12,264 | 55.00 | 42.00 |
Liabilities | -43.5% | 4,344 | 7,694 | 6,533 | 3,647 | 3,294 | 3,095 | 4,208 | 2,483 | 2,187 | 2,088 | 1,812 | 3,852 | 3,662 | 4,682 | 2,779 |
Current Liabilities | -43.5% | 4,344 | 7,694 | 6,533 | 3,647 | 3,294 | 3,095 | 4,208 | 2,483 | 2,187 | 2,088 | 1,812 | 2,830 | 2,640 | 3,660 | 2,779 |
Shareholder's Equity | -162.7% | -1,213 | 1,934 | 6,506 | 12,305 | 15,199 | 16,579 | 19,428 | 26,919 | 32,559 | 37,485 | 41,461 | 7,536 | 9,558 | - | - |
Retained Earnings | -5.4% | -62,764 | -59,544 | -54,982 | -48,987 | -45,875 | -44,354 | -41,367 | -33,725 | -27,840 | -22,703 | -18,586 | -15,370 | -13,027 | -10,647 | -6,308 |
Additional Paid-In Capital | 0.1% | 61,551 | 61,478 | 61,488 | 61,292 | 61,074 | 60,934 | 60,795 | 60,645 | 60,400 | 60,189 | 60,047 | 22,906 | 22,585 | 6,432 | 3,576 |
Shares Outstanding | 0% | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 1,171 | 498 | 445 | 395 | 315 | - |
Float | - | - | - | - | 9,399 | - | - | - | 14,615 | - | - | - | 9,367 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -156.7% | -7,729 | -3,011 | -2,651 | -2,182 | -2,008 | -1,567 | -5,498 | -4,736 | -6,044 | -4,922 | -4,742 | -1,797 | -3,080 | -150 | -643 | -368 | -222 | - |
Share Based Compensation | 854.8% | 73.00 | -9.63 | 196 | 218 | 141 | 138 | 151 | 245 | 211 | 141 | 142 | 321 | 370 | 336 | 435 | 572 | 131 | - |
Cashflow From Financing | - | 454 | - | - | - | - | - | - | - | - | 51.00 | 35,989 | - | 15,290 | -50.88 | 483 | 541 | 425 | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
OPERATING EXPENSES | ||
General and administrative (net of insurance reimbursement of $1,250,000 during the three months ended March 31, 2023 - See Note 5) | $ 1,689,182 | $ 415,451 |
Research and development | 1,613,275 | 1,235,614 |
Total operating expenses | 3,302,457 | 1,651,065 |
Loss from operations | (3,302,457) | (1,651,065) |
OTHER INCOME | ||
Other income | 82,033 | 130,531 |
Loss before income taxes | (3,220,424) | (1,520,534) |
Income taxes | ||
Net loss | $ (3,220,424) | $ (1,520,534) |
Basic net loss per share (in Dollars per share) | $ (2.75) | $ (1.3) |
Basic weighted average common stock outstanding (in Shares) | 1,171,233 | 1,171,233 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash | $ 1,866,131 | $ 9,141,512 |
Prepaid expenses and other current assets | 1,264,276 | 486,833 |
Total current assets | 3,130,407 | 9,628,345 |
Total assets | 3,130,407 | 9,628,345 |
Current liabilities | ||
Accounts payable and accrued expenses | 1,843,791 | 1,694,024 |
Litigation liability | 2,500,000 | 6,000,000 |
Total current liabilities | 4,343,791 | 7,694,024 |
Total liabilities | 4,343,791 | 7,694,024 |
Commitments and contingencies | ||
Stockholders’ (deficit) equity | ||
Preferred stock, par value $0.00001, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024, and December 31, 2023 | ||
Common stock, $0.00001 par value; 100,000,000 shares authorized, 1,171,233 shares issued and outstanding as of March 31, 2024, and December 31, 2023 | 12 | 12 |
Additional paid-in capital | 61,551,163 | 61,478,444 |
Accumulated deficit | (62,764,559) | (59,544,135) |
Total stockholders’ (deficit) equity | (1,213,384) | 1,934,321 |
Total liabilities and stockholders’ (deficit) equity | $ 3,130,407 | $ 9,628,345 |